AAA acquires cancer antibody treatment from Dompé
This article was originally published in Scrip
Executive Summary
First-in-the-biotech-phonebook company, Advanced Accelerator Applications (AAA) has acquired from Dompé the rights to FabOvar, an iodine-131-labelled, fully-humanised monoclonal antibody fragment in preclinical development for ovarian carcinoma. The financial details of the transaction were not revealed by the companies.